Program
VX-581
A development code.
Its studies are mostly in Cystic Fibrosis, led by Vertex Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 22 open or running | phase 1since Dec 4, 2025 | Dec 4, 2025 | Jul 12, 2027phase 1 · NCT07283770 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 4, 2025First study: phase 1 study in Cystic FibrosisFirst studyNCT07283770 · 152 planned · United States
- Sep 4, 2026Phase 1 study in Cystic FibrosisNCT07813039 · 16 enrolled · United States
- Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770
Ahead
- Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisNCT07283770
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07813039Cystic Fibrosis · United States | 1 | Active, not recruiting | Oct 27, 2026 | 16 |
| NCT07283770Cystic Fibrosis · United States | 1 | Recruiting | Jul 12, 2027 | 152 |
How it is read
Names in the registry
- “VX-581”, 3 entries
Codes read as this program: VX581.
Conditions, from the studies’ own filings
- Cystic Fibrosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.